Liver Diseases Clinical Trial
Official title:
Safety and Efficacy of Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement
The purpose of this study is to evaluate the efficacy, safety, and adequacy of Endoscopic Ultrasound (EUS) Portal Pressure Gradient Measurement (PPGM) in patients undergoing EUS-guided liver biopsies.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | January 1, 2025 |
Est. primary completion date | January 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | INCLUSION CRITERIA - Age 18 years or older - Patient who has been referred for EUS procedure and direct PPG measurement and -undergoing EUS-guided liver biopsy - History of liver disease or suspected cirrhosis and considered for PPGM EXCLUSION CRITERIA - Patient is less than 18 or greater than 85 years of age - Patient is pregnant, breast-feeding, or planning to become pregnant during the course of the study - Patient is unwilling or unable to sign and date the informed consent - Patient for whom endoscopic procedures are contraindicated. |
Country | Name | City | State |
---|---|---|---|
United States | Methodist Dallas Medical Center | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
Methodist Health System |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Portal Pressure Gradient Measurements from Hepatic and Portal Veins | A catheter is inserted into the hepatic vein before hepatic venous pressure and portal vein pressure are recorded | 2 years | |
Secondary | Correlation between Portal Pressure Gradient Measurements and the presence or absence of portal hypertension | Statistical tests to determine relationship between portal pressure gradient measurements and portal hypertension | 2 years | |
Secondary | Clinical significance between portal pressure gradient measurement and portal hypertension | Presence of varices, hypertensive gastropathy, or thrombocytopenia. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05255042 -
Tissue Models for Liver Disease
|
||
Completed |
NCT04473482 -
Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Trial
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Completed |
NCT02917408 -
Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
|
||
Recruiting |
NCT03773887 -
Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease
|
N/A | |
Recruiting |
NCT00345930 -
DILIN - Prospective Study
|
||
Completed |
NCT00148031 -
Improving Hepatitis C Treatment in Injection Drug Users
|
Phase 4 | |
Terminated |
NCT00031135 -
Total Parenteral Nutrition-Associated Liver Disease
|
Phase 2 | |
Completed |
NCT00005305 -
Hepatitis Delta Infections in Hemophiliacs
|
N/A | |
Completed |
NCT00005304 -
Delta Hepatitis and Liver Disease in Hemophiliacs
|
||
Completed |
NCT00222664 -
Qidong Hepatitis B Intervention Study
|
Phase 4 | |
Recruiting |
NCT06195917 -
Robotic-assisted Percutaneous Transhepatic Puncture
|
N/A | |
Recruiting |
NCT04551742 -
Social & Contextual Impact on Children Undergoing Liver Transplantation
|
||
Completed |
NCT04782050 -
Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology Consultation
|
N/A | |
Completed |
NCT03614039 -
Effect of Probiotic and Smectite Gel on NAFLD
|
N/A | |
Recruiting |
NCT04518852 -
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
|
Phase 2 | |
Recruiting |
NCT05499585 -
Treating Pediatric NAFLD With Nutrition
|
N/A | |
Terminated |
NCT03396705 -
Liver Regeneration
|
||
Completed |
NCT04341012 -
Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases
|
||
Recruiting |
NCT05733832 -
A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease
|
N/A |